Bristol Myers Squibb reported Phase 3 results for its cereblon E3 ligase modulator mezigdomide, showing a 52% reduction in the risk of disease progression or death when added to Amgen’s Kyprolis (carfilzomib) and dexamethasone. In the SUCCESSOR-2 study, median progression-free survival reached 18 months versus 8.3 months with Kyprolis and dexamethasone alone. BMS also reported stronger response depth, including complete response rates that nearly tripled versus control, while safety signals were more pronounced with the combination—grade 3 or 4 adverse events were higher in the mezigdomide arm. Overall survival data were described as immature at the time of the update. The company said it will engage with regulators in the future, positioning mezigdomide as a potential successor to existing myeloma standards built on Revlimid and Pomalyst mechanisms.